Molecular and Cellular Biology, May 1999, p. 3736-3747, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Activation of Somatostatin Receptor II Expression by
Transcription Factors MIBP1 and SEF-2 in the Murine Brain
Ulrike
Dörflinger,1
Armin
Pscherer,2
Markus
Moser,3
Petra
Rümmele,2
Roland
Schüle,1 and
Reinhard
Buettner2,*
Institut für Experimentelle
Krebsforschung, Klinik für Tumorbiologie an der Universität
Freiburg, D-79106 Freiburg,1 Institut
für Pathologie, Universität Regensburg, D-93042
Regensburg,2 and Institut für
Pathologie, Klinikum der RWTH Aachen, D-52074
Aachen,3 Germany
Received 5 November 1998/Returned for modification 30 November
1998/Accepted 2 February 1999
 |
ABSTRACT |
Somatostatin receptor type II expression in the mammalian brain
displays a spatially and temporally very restricted pattern. In an
investigation of the molecular mechanisms controlling these patterns,
we have recently shown that binding of the transcription factor SEF-2
to a novel initiator element in the SSTR-2 promoter is essential for
SSTR-2 gene expression. Further characterization of the promoter
identified a species-conserved TC-rich enhancer element. By screening a
mouse brain cDNA expression library, we cloned a cDNA encoding the
transcription factor MIBP1. MIBP1 interacts specifically with both the
TC box in the SSTR-2 promoter and with the SEF-2 initiator-binding
protein to enhance transcription from the basal SSTR-2 promoter. We
then investigated SSTR-2, SEF-2, and MIBP1 mRNA expression patterns in
the developing and adult murine brain by Northern blotting and in situ
hybridization. While SEF-2 is widely expressed in many neuronal and
nonneuronal tissues, MIBP1 expression overlapped precisely with
expression of SSTR-2 in the frontal cortex and hippocampus. In summary,
our data for the first time define a regulatory role for the
transcription factor MIBP1 in mediating spatially and temporally
regulated SSTR-2 expression in the brain.
 |
INTRODUCTION |
The effects of somatostatin (SST)
hormones are mediated by a family of five different, highly conserved
receptors, SSTR-1 to SSTR-5 (2, 13, 18, 21, 32, 33), which
belong to the class of seven helix transmembrane-spanning receptors. A
series of detailed studies, employing Northern blotting, reverse
transcriptase PCR and in situ hybridization, revealed complex gene
type-specific expression patterns in many regions of the central
nervous system. In particular, regions of intense SSTR-2 expression in
the brain comprise the hypothalamic-hypophyseal system, which regulates the adenohypophyseal release of growth hormone, thyroid-stimulating hormone, and prolactin and the widespread somatostatinergic system in
the frontal cortex and the hippocampus, modulating many cognitive and
vegetative functions (5, 10). Furthermore, spatially and
temporally regulated SSTR-2 expression patterns have been observed
during embryonic brain and peripheral nerve development, suggesting
that somatostatin signalling exerts functions during neurogenesis
(9, 12).
In an investigation of molecular mechanisms controlling the expression
pattern of SSTR-2, we recently provided an initial study of the human
SSTR-2 promoter (20). We demonstrated that initiation of
mRNA transcription is dependent on the presence of an E-box-binding
site for the basic helix-loop-helix (bHLH) transcription factor SEF-2.
SEF-2 function involves tethering of transcription factor IIB (TFIIB),
a component of the basal transcription machinery, to the SSTR-2
initiator. Despite being an essential factor for basal promoter
activity, SEF-2 alone is insufficient to mediate enhanced
transcriptional activity of the SSTR-2 gene.
Therefore, we extended our SSTR-2 promoter analysis. In the present
study, we demonstrate that a TC-rich species-conserved binding site,
which is located 5' adjacent to the E box, is required for enhanced
promoter activity. Expression cloning revealed that a large zinc finger
nuclear protein of previously unknown function, MIBP1, binds
specifically to the TC box and activates transcription from the SSTR-2 promoter.
 |
MATERIALS AND METHODS |
Tissue culture and transient transfections.
N2A, NGP, Lan-1,
GHFT-1, HeLa, and COS-1 cells were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum.
Transient-transfection assays were performed by a standard calcium
phosphate coprecipitation method (8). Luciferase activity
was quantified as recommended by the manufacturer (Promega) in a
luminometer (ML 3000; Dynatech). Relative light units were normalized
to the protein concentration determined by the Bradford dye assay
(Bio-Rad, Richmond, Calif.). All experiments were repeated at least
five times, and standard deviations were <10%.
Reporter and expression plasmids.
The SSTR-2 promoter-LUC
reporter series was generated by cloning single copies of the listed
oligonucleotides into the multiple-cloning sites of plasmids pGL2LUC or
TK-LUC (Promega, Madison, Wis.). Identical oligonucleotides were used
for generation of the reporter plasmids and as probes for gel shifts.
The reporter plasmids are as follows (the SSTR-2 promoter E box is
highlighted in boldface, and point mutations are underlined): Inr,
AATCTTCCTCTTTTCCTTCCAGATGTCACACTGGATCC; M1,
AATCTTCCTCTTTTCCTTC; M2,
CAGATGTCACACTGGATCC; M6,
AATCTTCCTCTTTTCCTTCCAAATGTCACACTGGATCC; M13, TTTTCCTTCCAGATGTCACACTGGATCC; M14,
CCAGATGTCACACTGGATCC; M15,
AATCTTCCTCTTTTCCTTCCAG; M16,
AATCTTGGTCTTTTGGTTCCAGATGTCACACTGGATCC; M17,
AATCTTCCTCTTTTGGTTCCAGATGTCACACTGGATCC;
M18,
AATCTTGGTCTTTTCCTTCCAGATGTCACACTGGATCC; M19, TCTTCCTCTTTTCCTTCCAG; M20,
TCTTCCTCTTT; M21,
TTTTCCTTCCAGATG; and M50,
CATATCTAGGTCATGACCTAGATATGAGCT. The oligomer M50, which was
used as a nonspecific competitor, contains an unrelated RZR
-binding site.
Cytomegalovirus promoter-based expression plasmids pCMX.PL1,
pCMX.PL2 (29), pCMX-SEF-2, GST-SEF-2, and
GST-bHLH-SEF-2 were described previously (20). To
construct GST-
-bHLH-SEF-2, the entire SEF-2 cDNA deleted by the
C-terminal bHLH domain was PCR amplified with a T7 primer and a
specific EcoRI-modified SEF-2 primer
(5'-TTGGAATTCATGCATCACC) and ligated into the
EcoRI-SmaI sites of pGEX 4T1 (Pharmacia,
Freiburg, Germany). To construct pCMX-MIBP1, a 7.5-kb
DraI-NsiI-digested rat cDNA fragment (a generous gift from Kenshi Hayashi, Fukuoka, Japan) encoding the full-length MIBP1 protein was inserted at the EcoRV-PstI site
of pCMX.PL2. To construct the GST-MZF expression plasmid, a cDNA
fragment of rat MIBP1 coding for the C-terminal zinc finger (amino
acids 1740 to 2110) was PCR amplified and inserted at the
EcoRI-SmaI site of pGEX4T1 (Pharmacia).
DNA-binding studies.
Preparation of whole-cell extract and
purification of glutathione S-transferase (GST) fusion
proteins was described by Buettner et al. (3). In vitro
translation reactions were performed with reticulocyte lysate as
specified by the manufacturer (TNT; Promega). Purified GST fusion
protein (0.5 µg), 4 µl of whole-cell extract, or 2 µl of in vitro
translation product was mixed with 10 mM HEPES (pH 7.8)-80 mM
KCl-10% glycerol-5 mM MgCl2-1 mM dithiothreitol-0.5 µg of poly(dG-dC) and incubated for 15 min on ice. Subsequently 1 ng
of 32P-labelled probe was added. For supershift assays, the
following antibodies were added to the reaction mix: anti-GST mouse
monoclonal immunoglobulin G1 (Santa Cruz Biotechnology, Santa Cruz,
Calif.) or anti-MIBP1 (
-P-M) rabbit polyclonal serum
(26). After incubation for 30 min on ice, the samples were
separated on a 4% polyacrylamide gel in 0.5× Tris-borate-EDTA (TBE)
at 4°C. After electrophoresis, the gels were dried and subjected to autoradiography.
In vitro protein-binding assay.
Purified recombinant GST,
GST-full-length SEF-2, GST-bHLH-SEF-2, or GST-
-bHLH-SEF-2 (2 µg) was coupled for 1 h at 4°C to 50 µl of
glutathione-Sepharose 4B beads (Pharmacia) and then washed three times
with 1 ml of GST binding buffer (20 mM HEPES [pH 7.5], 150 mM KCl, 25 mM MgCl2, 10 mM dithiothreitol, 0.1 mM EDTA, 0.15% Nonidet
P-40). The matrix was resuspended in 500 µl of GST binding buffer,
incubated for 1 h at 4°C with 5 µl of
[35S]methionine-labelled MIBP1 protein, and again washed
three times. Finally, the proteins were eluted, and denatured in
Laemmli's buffer at 95°C for 10 min, and separated by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (6% polyacrylamide).
Screening of genomic and
gt11 cDNA expression libraries.
The murine SSTR-2 promoter was isolated from a murine SVJ129 genomic
library (Stratagene, La Jolla, Calif.) with the human SSTR-2 cDNA as a
probe by using standard methods (23). A total of 1.8 × 105 plaques of a commercially available murine brain cDNA
library in the expression vector
gt11 were screened by using a
tetrameric SSTR-2 Inr-binding site as a probe. A detailed protocol for
expression screening has been published recently (20). The
C-terminal clone of MIBP1, isolated by expression screening, was used
to rescreen and isolate the murine full-length cDNA.
Northern blots and in situ hybridizations.
Northern blots
(Clontech) were hybridized in 50% formamide-5× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-1% SDS-150 µg of tRNA per
ml-250 µg of single-stranded DNA per ml at 42°C for 16 h.
Final washes were done in 0.1× SSC-0.01% SDS at 65°C for 45 min.
As probes, cDNA fragments of SEF-2 (nucleotides 1 to 1795) and MIBP1
(4469 to 5388) were used. A detailed protocol for in situ hybridization
of paraffin-embedded mouse embryo slides has been published previously
(15). As probes, the same cDNA fragments used for Northern
blots were transcribed as sense and antisense
35S-UTP-labelled cRNAs.
Reverse transcriptase PCR.
Reverse transcription was
performed with 3 µg of total cellular RNA as described previously
(3), except that pd(N)6-primers (2 µg; Pharmacia) were
used instead of sequence-specific primers. PCR amplification, as
described previously (16), was performed with the following
profile: SSTR-2 (35 cycles of 1 min at 94°C, 1 min at 56°C, and 1 min at 72°C), SEF-2 (30 cycles of 1 min at 94°C, 1 min at 63°C,
and 1 min at 72°C), MIBP1 (30 cycles of 1 min at 94°C, 1 min at
60°C, and 1 min at 72°C), and
-actin (30 cycles of 1 min at
94°C, 1 min at 60°C, and 1 min at 72°C). The following specific
PCR primers were used: human SSTR-2 sense, GGC TCC TCT AAG AGG AAG AAG;
rodent SSTR-2 sense, GGG TCG TCC AAG AGG AAA AAG; SSTR-2 reverse, TCT
CCA TTG AGG AGG GTC CTC; SEF-2 sense, CGC CAG GCT ATC CTT CCT CCA;
SEF-2 reverse, CCT GTC CTC CAT TTC TAG ACC; MIBP1 sense, GCT TCA TGG
TGC ATT AGT TCC; MIBP1 reverse, GGC TCG GTT TGT TTG GAT CCA;
-actin
sense, TGA CGG GGT CAC CCA CAC TGT G;
-actin reverse, CTA GAA GCA
TTT GCG GTG GAC. Then 10% of the PCR products were fractionated on 2% agarose gels and subjected to Southern blot analysis.
 |
RESULTS |
To identify species-conserved motifs in the SSTR-2 promoter, we
aimed to determine the murine SSTR-2 promoter sequence for comparison
with the previously characterized human promoter (20). Therefore, the murine SSTR-2 gene was isolated and sequenced in the
5'-flanking region. As displayed in Fig.
1A, two sequence motifs highly conserved
between the human and murine promoters were detected: (i) an E box
spanning residues
11 to
6, which was previously identified as the
core initiator element of the human promoter indispensible for basal
SSTR-2 promoter function (20); and (ii) a TC box 5' adjacent
to the E box, with the core sequence TCTTTTCC and a further
TCT(T/G)C(C/T) 5' extension. Further upstream, no other significant
homology between the human and murine 5'-flanking regions was detected.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Nucleotide sequence of the human (hu) SSTR-2
promoter (top) from positions +8 to 35 with respect to the mRNA
initiation site and comparison to the murine (mu) SSTR-2 promoter
(bottom). A conserved TC-rich sequence (TC box) is printed in boldface,
and the E box from residues 11 to 6 is shown in italics. (B)
Identification of cis-regulatory elements in the human
SSTR-2 promoter. The indicated reporter plasmids (500 ng) were
transfected into N2A, NGP, and GHFT-1 cells (rows 1 to 10). The mRNA
initiation sites are indicated by two arrows. The E box and the TC box
are shown as rectangles. The numbers indicate positions of the
respective nucleotides within the human SSTR-2 promoter. The reporter
M6-LUC, which contains a single point mutation in the E box (MUT), is
shown in row 8, and reporters which contain the double point mutations
in the TC box (CC to GG) are shown in rows 5 to 7.
|
|
To investigate which of these sequence motifs harbor critical
cis-regulatory elements, we cloned a series of human SSTR-2 promoter deletion mutants into the promoterless luciferase reporter plasmid pGL2basic and tested these reporters in transient-transfection assays (Fig. 1B). Consistent with previous results, a luciferase reporter driven by the SSTR-2 promoter fragment spanning residues
30
to +8 revealed high levels of promoter activity in murine and human
neuroblastoma cells (N2A and NGP) and also in rat pituitary cells
(GHFT-1). This SSTR-2 promoter fragment (designated Inr in Fig. 1B) has
been referred to as the SSTR-2 initiator (20). Deletion of
the first half of the TC box (mutant M13) reduced SSTR-2 promoter
activity significantly, whereas further deletion of the entire TC box
(M14) caused reduction of activity to background levels. Introduction
of CC-to-GG point mutations into the TC elements (M16 to M18)
significantly impaired promoter function, indicating that an intact TC
box is required for enhanced activity. In addition to the TC elements,
SSTR-2 promoter function was critically dependent on the E-box core
element. An intact TC box in the context of a partially deleted E box
(M15) or an E box harboring a G-to-A-point mutation (M6) entirely
failed to activate the expression of the luciferase reporters. In
summary, we concluded from these results that the TC box harbors an
important, species-conserved cis-regulatory element, which
confers enhanced activity to the basal SSTR-2 promoter.
We therefore aimed to clone proteins interacting specifically with the
TC-box element in the SSTR-2 promoter. A murine brain
gt11
expression library was screened by using the SSTR-2 promoter fragment
shown in Fig. 1A. By screening 2 × 105 phage plaques,
a cDNA clone was isolated, which encoded the C-terminal zinc finger
domain of the murine MIBP1 homolog. MIBP1 codes for a large
sequence-specific DNA-binding zinc finger protein of unknown physiological function. MIBP1 was previously isolated from rat (11) and human cDNA libraries and was also referred to as
MBP-2/HIV-EP2 (17, 31). Furthermore, two partial MIBP1 cDNA
fragments were isolated previously and designated AGIE-BP1 and AT-BP1
(14, 22). The cDNA insert from our expression screen was
then used to rescreen a brain cDNA library. A total of 16 independent
phage inserts, spanning the entire MIBP1 open reading frame, were
isolated. The open reading frame codes for a protein of 2,431 amino
acids with an expected molecular mass of approximately 270 kDa. We
determined a very high degree of homology, with only 140 amino acid
exchanges between the mouse and rat sequences, 86 of which are
conservative. The entire murine, rat, and human MIBP1 (MBP-2/HIV-EP2)
peptide sequences are displayed in Fig.
2. As noted previously
(11), MIBP1 harbors two clusters of
C2H2 zinc fingers in the N terminus (amino
acids 191 to 241) and in the C terminus (amino acids 1785 to 1835),
respectively. A putative nuclear translocation signal is located
between amino acids 930 and 935, and an acidic region is located
between amino acids 1883 and 1910. To determine whether MIBP1 binds to
the SSTR-2 promoter in a sequence-specific manner, we expressed either
the full-length MIBP1 protein by in vitro translation or a C-terminal
fragment spanning amino acids 1740 to 2110 including the C-terminal
zinc finger cluster as a GST fusion protein. These proteins were then
used in a series of gel shift experiments. Two specific retarded
complexes resulted from coincubation of in vitro-translated MIBP1 with
the SSTR-2 TC box (Fig. 3A, lane 2). Both
complexes were specifically competed by a 50- or 100-fold molar excess
of the unlabelled SSTR-2 wild-type promoter sequence (lanes 3 and 4, Inr). We then performed a series of competition experiments with
various mutated binding sites. Mutants M19 and M20 but not a 3'
fragment harboring the E box (mutant M14) or a central fragment (mutant
M21) were able to compete, indicating that the TC box is the specific
target of MIBP1 binding (Fig. 3A). Furthermore, the same mutations that
significantly reduced (M16 to M18) or completely abolished (M14) SSTR-2
Inr function were also drastically impaired in their ability to compete MIBP1 DNA binding.


View larger version (89K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of the murine (mu), rat, and human (hu) MIBP1
peptide sequences. The rat and human amino acid residues differing from
the respective residues of the murine protein are indicated below the
murine sequence. Especially well conserved motifs include the N- and
C-terminal zinc fingers (doubly underlined), the putative nuclear
localization signal (boxed), and the acidic region (underlined).
|
|



View larger version (96K):
[in this window]
[in a new window]
|
FIG. 3.
Sequence-specific binding of MIBP1 to the human SSTR-2
promoter. (A) Electrophoretic mobility shift assays were performed with
a 32P-labelled oligonucleotide containing the promoter
sequence from positions 28 to 18 (M20) and in vitro-translated
MIBP1 protein (lane 2). Competition experiments were performed with 50- and 100-fold molar excesses of the indicated competitors. The MIBP1
TC-box complexes CI and CII are competed by the oligonucleotides Inr,
M19, and M20. Oligonucleotides M21, containing a partially deleted TC
box, and M14, representing the 3' promoter region harboring the E box,
fail to compete. Competition by oligonucleotides M16, M17, and M18,
representing point-mutated TC boxes, is drastically impaired. As a
control an unrelated competitor, M50, also failed to compete. (B) The
C-terminal MIBP1 zinc finger binds to the SSTR-2 promoter.
Electrophoretic mobility shift assays were performed with the Inr
oligonucleotide from nucleotides 30 to +8 and purified recombinant
GST fusion protein (lane 1). A 100-fold molar excess of unlabelled Inr
oligonucleotide, oligonucleotide M1, or oligonucleotide M19 competed
with formation of the MIBP1-Inr complexes CI and CII. The control
oligonucleotides M2 and M21 failed to compete. (C) MIBP1 binds to the
SSTR-2 promoter in vivo. Whole-cell extract prepared from GHFT-1 cells
(4 µl) was incubated with 1 ng of 32P-labelled
oligonucleotide M19 (lanes 2 to 7). Complex CI is specifically competed
by a 100-fold molar excess of oligonucleotides M19 and Inr. In
contrast, the unrelated oligonucleotide M50 does not compete. To
establish the composition of complex CI, the electrophoretic mobility
shift assay mixture was challenged with an antiserum directed against
the C-terminal zinc finger domain of MIBP1 (lane 6) or an unrelated
anti-GST control antibody (lane 7). The very faint supershifted MIBP1
complex is labelled -P-M-C.
|
|
We further observed two specific DNA-protein complexes resulting from
coincubation of the SSTR-2 Inr with the bacterially expressed
C-terminal MIBP1-GST fusion protein (Fig. 3B). Consistently, 5' SSTR-2
fragments spanning either the entire TC box (mutants M1 and M19) or the
full Inr sequence competed for specific binding of the GST-MIBP1
protein. In contrast, both a 3' fragment spanning the E box (mutant M2)
and a central fragment (M21) failed to compete. Taken together, these
data reveal that the TC box of the SSTR-2 promoter represents a
sequence-specific binding site for MIBP1 and that the C-terminal MIBP1
zinc finger cluster is sufficient for binding to the TC box.
Next we addressed whether MIBP1 binding to the SSTR-2 promoter also
occurs in vivo and performed gel mobility shift assays with protein
extracts from cells that express SSTR-2 mRNA. We coincubated GHFT-1
extracts with the SSTR-2 promoter fragment M19 (harboring the intact TC
box) and challenged the band shift with a polyclonal serum raised
against the C-terminal zinc finger domain of MIBP1. The most prominent
band shift complex, labelled CI in Fig. 3C, was specifically competed
by a 100-fold molar excess of unlabelled oligonucleotides M19 and Inr,
respectively (Fig. 3C, lanes 2 to 4). In contrast, an unrelated
competitor (M50) failed to compete (lane 5). Addition of the polyclonal
MIBP1 antiserum interfered with formation of the band shift complex CI.
A small portion of complex CI supershifted as a very faint and large
DNA-protein complex, which was difficult to visualize (labelled
-P-M-C in Fig. 3C, lane 6). Disruption of complex CI was a specific
effect of the MIBP1 antiserum and was not observed by challenging the electrophoretic mobility shift assay mixture with an unrelated anti-GST
control antiserum (lane 7). In summary, these data provide further
evidence for sequence-specific binding of MIBP1 protein to the SSTR-2
promoter both in vitro and in vivo.
To investigate whether MIBP1 acts as a transcriptional activator of the
SSTR-2 gene, we measured the effect of MIBP1 overexpression on the
activity of the SSTR-2 promoter. The entire MIBP1 open reading frame
was cloned into the expression plasmid pCMX.PL1 and transfected
together with the SSTR-2 promoter luciferase reporter construct
(nucleotides
30 to +8 as shown in Fig. 1A) into the neuroblastoma
cell line N2A and the pituitary cell line GHFT-1. We chose these two
cell lines because they represent tissues, i.e., neurons and
pituitary gland cells, that physiologically express SSTR-2
mRNA (10, 24, 25, 28). Cotransfection of MIBP1 expression
plasmid with wild-type SSTR-2 promoter reporter resulted in significant
induction of luciferase expression in both N2A and GHFT-1 cells (Fig.
4A and B). In contrast, MIBP1 failed to
activate luciferase expression from all SSTR-2 promoter constructs
harboring either deletions (mutants M13 and M14) or point mutations
(M16 to M18) in the MIBP1 TC-rich binding site. Consistent with
previous results that mRNA initiation from the SSTR-2 promoter is
critically dependent on the interaction of the bHLH protein SEF-2 with
the E box, a single point mutation within the E-box sequence (mutant
M6) or partial deletion of the 3' half of the E box resulted in
complete loss of promoter activity, irrespective of MIBP1 expression.
Importantly, MIBP1 overexpression did not change luciferase
expression from a simian virus 40 promoter control plasmid,
indicating that the effect of MIBP1 as a transcriptional activator of
the SSTR-2 Inr in N2A and GHFT-1 cells was promoter specific.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
(A and B) MIBP1 mediates transcriptional activation of
the human SSTR-2 promoter in N2A cells (A) and GHFT-1 cells (B). The
luciferase activity of the reporter constructs Inr-LUC, the mutated Inr
reporter constructs M13-LUC to M18-LUC, M6-LUC, and the promoterless
control plasmids basic pGL ( ) or SV40-LUC is displayed as open bars.
Shaded bars represent promoter activity in cells cotransfected with 200 ng of pCMX-MIBP1 expression plasmid. (C) MIBP1 mediates transcriptional
activation via the TC box of the human SSTR-2 promoter. Samples (500 ng) of the reporter construct M19-TK-LUC or M20-TK-LUC containing
either the Inr sequence from nucleotides 28 to 9 (TC box [Fig.
1]) or 28 to 18 in front of the thymidine kinase (TK) promoter were
cotransfected with 200 ng of pCMX-MIBP1 expression plasmid (shaded
bars) or with empty pCMX plasmid (open bars). As a control, the
pCMX-MIBP1 expression plasmid was also cotransfected with the
promoterless TK-LUC reporter.
|
|
In addition, the SSTR-2 promoter TC box mediated transcriptional
activation by MIBP1 in the context of an unrelated promoter. When we
cloned single copies of the SSTR-2 promoter fragments M19 and M20,
harboring a functional TC box, in front of a TK-LUC reporter, we
observed three- to fourfold MIBP1-dependent reporter activation.
Importantly, the activity of the parental TK-LUC reporter, lacking a TC
box, was not changed by MIBP1 (Fig. 4C).
Since the MIBP1- and SEF-2-binding sites in the human and murine SSTR-2
promoter are located in very close proximity, we further examined a
potential protein-protein interaction between MIBP1 and SEF-2.
Therefore, GST fusion proteins containing full-length SEF-2 protein,
the C-terminal bHLH domain of SEF-2, or SEF-2 with the bHLH domain
deleted (
-bHLH-SEF-2) were immobilized to glutathione-coupled Sepharose and incubated with in vitro-translated
[35S]methionine-labelled MIBP1 protein. As shown in Fig.
5, both the C-terminal bHLH domain and
the full-length SEF-2 protein, but not
-bHLH-SEF-2, retained
specifically in vitro-translated MIBP1 protein. The interaction was
specific for the bHLH domain of SEF-2, since GST fusion proteins of E12
and E47 did not interact with MIBP1. These data strongly suggest that
the evolutionarily conserved close proximity of the SSTR-2 TC-box and
E-box elements in the human and murine promoters facilitate direct
protein-protein interaction between MIBP1 and SEF-2.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
MIBP1 and SEF-2 proteins interact in vitro. The GST
pull-down experiment was performed with 5 µl of in vitro-translated
[35S]methionine-labelled MIBP1 protein (input) and
immobilized, recombinant GST-SEF-2 fusion protein, GST-bHLH-SEF-2,
GST- -bHLH-SEF-2, GST-E12, or GST-E47. The control protein GST
failed to interact with ivt-MIBP1.
|
|
To extend our studies beyond the analysis of cell lines in vitro, we
investigated the pattern of MIBP1 mRNA in comparison with expression of
SEF-2 and SSTR-2 in vivo. Therefore, Northern blots of adult human and
embryonic murine tissues were hybridized with a MIBP1 probe. A single
MIBP1 mRNA approximately 9.5 kb long was detected in human brain and
skeletal muscle and further in murine heart, brain, lung, and skeletal
muscle and at very low levels in murine liver (Fig.
6A and B). Interestingly, mRNA expression of MIBP1 in brain, heart, skeletal muscle, and lung overlapped precisely with expression of SSTR-2 (21, 32) and SEF-2
(20) mRNA. During murine embryogenesis, MIBP1 expression
started at stage E10.5 and persisted through all later stages (Fig.
6C). Finally, we examined by reverse transcriptase PCR analysis the expression patterns of SSTR-2, SEF-2, and MIBP1 mRNA in a panel of
selected neural, pituitary gland, and epithelial cell lines (Fig. 6D).
As expected, coexpression of SSTR-2, SEF-2, and MIBP1 was detected in
neural cell lines (N2A, NGP, and Lan-1) and in pituitary gland cells
(GHFT-1) but not in epithelial cell lines (HeLa and COS-1).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 6.
Multiple tissue Northern blots of adult human (A) and
adult murine (B) tissues and developmental stages E9.5 to E19.5 of
murine embryogenesis (C). A single MIBP1 transcript of approximately
9.5 kb is indicated by an arrow. Abbreviations: ht (heart), br (brain),
pl (placenta), lu (lung), li (liver), skm (skeletal muscle), kd
(kidney), pa (pancreas), sp (spleen), te (testis). -Actin control
hybridizations or ethidium bromide-stained 18S RNA are shown below the
blots. (D) Reverse transcriptase PCR amplification of SSTR-2, SEF-2,
and MIBP1 transcripts with 3 µg of total cellular RNA from the
neuroblastoma cell lines (N2A, NGP, and Lan-1), pituitary gland cells
(GHFT-1), and epithelial cells (HeLa and COS-1). Ethidium bromide
(Et-br)-stained gels and Southern blots probed with the respective
phospholabelled probes are shown in parallel.
|
|
To explore in greater detail the expression patterns of MIBP1, SEF-2,
and SSTR-2 mRNA in the adult brain and during embryonic development, we
performed a series of in situ hybridizations to tissue sections of
paraffin-embedded murine brain and embryo specimens. To avoid signals
resulting from cross-hybridization, we prepared cRNA probes from the
same MIBP1 partial clone that we used for the Northern blots shown in
Fig. 6. In the adult brain (Fig. 7), specific signals resulting from MIBP1 and SEF-2 mRNA expression were
colocalized to the cerebral cortex, the hippocampus, and corpora
amygdala and, further, to a discrete layer of the cerebellar cortex
overlapping precisely with regions of SSTR-2 mRNA distribution (10). In mouse embryos dissected at stages E13.5 (Fig.
8A and B) and E15.5 (Fig. 8C and D),
specific MIBP1 signals were detected in restricted areas of the
anterior neural tube over the primordial frontal cortex, in the spinal
cord, in the dorsal root ganglia, and in developing skeletal muscle. As
described previously (27) and further confirmed by our in
situ hybridizations (Fig. 8A), SEF-2 mRNA expression patterns were much
less restricted and highly abundant in many tissues, including the
anterior neural tube, hindbrain, spinal cord, dorsal root ganglia,
skeletal muscle, and subepidermal connective tissue. In summary, these
studies revealed that SSTR-2-positive tissues in embryonic and adult
mice overlap precisely with patterns of MIBP1 and SEF-2 coexpression.

View larger version (81K):
[in this window]
[in a new window]
|
FIG. 7.
Expression of SEF-2 and MIBP1 in adult mouse brain
(sagittal sections) analyzed by in situ hybridization. The specificity
of all the reactions was controlled by hybridizations with sense cRNA
probes under identical conditions (data not shown). (A) Specific SEF-2
signals were obtained in cortex (cx), hippocampus (h), cerebellum (cb),
and olfactory bulb (o). (B) Specific MIBP1 signals were obtained
overlapping with all of the SEF-2-positive structures.
|
|

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 8.
In situ hybridization of mouse embryos of gestational
stage E13.5 (A and B) and E15.5 (C and D) with SEF-2 and MIBP1 cRNA
probes. The specificity of all the reactions was controlled by
performing hybridization with sense probes under identical conditions
(data not shown). (A and C) SEF-2 expression in the dermis (d),
forebrain (f), intervertebral discs (i), gut (g), cartilage (c), and
cortex (cx). (B and D) MIBP1 expression in the forebrain (primordium of
the cortex [cx]), tongue (t), spinal ganglia (s), lower-jaw
mesenchyme (m), and olfactory epithelium (o).
|
|
 |
DISCUSSION |
During the last few years, a family of five G-protein-coupled,
transmembrane-spanning receptors, which mediate the
pleotrophic effects of SSTs, have been isolated (reviewed in
reference 19). First, functional studies have
implicated SST as a key regulatory molecule in the
hypothalamic-hypophyseal axis through central control of growth
hormone-releasing hormone-producing neurons in the arcuate nucleus
(28). Second, SST modulates a large variety of cognitive and
vegetative functions, including sleep behavior (1a), which
involve the widespread somatostatinergic system in cortical and
subcortical brain regions. Third, a variety of effects on peripheral
target tissues, including release of hormones from the
gastroenteropancreatic endocrine system and modulation of muscle
contraction, especially in smooth muscle and vascular wall muscle
cells, have been identified (4). All of these functions involve interactions between SST and the receptor subtype SSTR-2, which
displays specific expression patterns on the surface of the respective
target cells.
Furthermore, specific SSTR expression patterns have been detected
during embryonal development of the rodent central and peripheral nervous systems. The precise role of somatostatinergic signalling during embryogenesis remains to be determined; however, transient changes in these expression patterns during development suggest that
SSTRs modulate the differentiation and plasticity of neural cells
(9). Although SSTR expression patterns in developing and
adult nervous systems have been described in detail (7, 25)
and reveal a high degree of conservation even among different amphibian
and mammalian species (30), the transcriptional mechanisms which specify these patterns are entirely unknown.
The results of our study clearly show that a combinatorial set of two
different transcription factors, the bHLH factor SEF-2 and the zinc
finger protein MIBP1, bind in a sequence-specific manner to the SSTR-2
Inr and mediate enhanced transcriptional activity. Overlapping
expression patterns of SEF-2 and MIBP1 in both embryonal and adult
tissues coincide with spatially and temporally restricted expression
patterns of SSTR-2, which have been studied in detail previously by
using both in situ hybridization and receptor-specific radiolabelled
ligands (1, 10, 12, 28a, 28b). These data define for the
first time a transcriptional function of MIBP1 and imply that this
transcription factor plays an important role in the development of
nervous and neuroendocrine tissues.
The characterization of MIBP1 as a transcription factor that exhibits
sequence-specific DNA-binding properties to the SSTR-2 TC box came as a
surprise. A number of previous studies have shown that the rat MIBP1
homolog, the human MBP2 homolog, the partial MIBP1 clone AGIE-BP1, and
the sequence-related transcription factor PRDII-BP1 bind specifically
to NF-
B-like motifs with the consensus GGG N(4-5)CC
(6, 11, 14, 17, 22). We therefore speculate that MIBP1
utilizes the multiple zinc finger clusters to bind to a number of
promiscuous GC- or TC-rich binding sites. The huge MIBP1 peptide
surface could thereby serve multiple functions, possibly as an adapter
to other proteins or as an unwinding factor for TC- or GC-rich promoter
regions. Clearly, the close proximity between the MIBP1- and the
SEF-2-binding sites in the SSTR-2 has been evolutionarily conserved.
These data suggest strongly that a direct interaction between the two
proteins, which we observed in vitro, is functionally relevant.
We have previously shown that specific binding of SEF-2 to the E box is
sufficient to initiate basal transcription from the SSTR-2 initiator.
SEF-2 was able to recruit the basal transcription machinery via direct
interaction with TFIIB and thereby to mediate gene transcription
independently of a TATA element (20). We now show that MIBP1
binds on DNA in close proximity to SEF-2 and that the two proteins can
physically interact in vitro. In addition, MIBP1 mediates enhanced
SEF-2-dependent SSTR-2 promoter activity in vivo. Since SEF-2
expression occurs in many tissues, including neural, inflammatory, and
muscle cells, MIBP1 seems to direct enhanced transcriptional activity
to a specific promoter. The combinatorial activation of SSTR-2 gene
expression by SEF-2 and MIBP1 may therefore specify SSTR-2 expression
not only in neural cells but also under various physiological or
pathophysiological conditions in smooth muscle and inflammatory cells.
 |
ACKNOWLEDGMENTS |
We are indebted to Kenshi Hayashi (Fukuoka, Japan) for providing
the rat MIBP1 cDNA, to Richard B. Gaynor (University of Texas, Dallas)
for providing the MIBP1/PRDII-BF1 zinc finger antiserum, to Pamela
Mellon (San Diego, Calif.) for providing the cell line GHFT-1, and to
Silvia Seegers for help with sequencing.
This work was supported by grants from the DFG to R.B. and R.S.
Equal contributions to this work were made by U.D. and A.P. Therefore,
both should be considered first authors.
 |
FOOTNOTES |
*
Corresponding author. Present address: Institute for
Pathology, University Hospital, RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany. Phone: (49) 241-8089281. Fax: (49) 241-8888439. E-mail: Buettner{at}pat.rwth-aachen.de.
 |
REFERENCES |
| 1.
|
Beaudet, A.,
D. Greenspun,
J. Raelson, and G. S. Tannenbaum.
1995.
Patterns of expression of SSTR1 and SSTR2 somatostatin receptor subtypes in the hypothalamus of the adult rat: relationship to neuroendocrine function.
Neuroscience
65:551-561[Medline].
|
| 1a.
|
Beranek, L.,
F. Obal, Jr.,
P. Taishi,
B. Bodosi,
F. Laczi, and J. M. Krueger.
1997.
Changes in rat sleep after single and repeated injections of the long-acting somatostatin analog octreotide.
Am. J. Physiol.
273:1484-1491.
|
| 2.
|
Bruno, J. F.,
Y. Xu,
J. Song, and M. Berelowitz.
1992.
Molecular cloning and functional expression of a brain-specific somatostatin receptor.
Proc. Natl. Acad. Sci. USA
89:11151-11155[Abstract/Free Full Text].
|
| 3.
|
Buettner, R.,
P. Kannan,
A. Imhof,
R. Bauer,
S. O. Yim,
R. Glockshuber,
M. W. Van Dyke, and M. A. Tainsky.
1993.
An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2.
Mol. Cell. Biol.
13:4174-4185[Abstract/Free Full Text].
|
| 4.
|
Dimech, J.,
W. Feniuk,
R. D. Latimer, and P. P. Humphrey.
1995.
Somatostatin-induced contraction of human isolated saphenous vein involves sst2 receptor-mediated activation of L-type calcium channels.
J. Cardiovasc. Pharmacol.
26:721-728[Medline].
|
| 5.
|
Epelbaum, J.,
P. Dournaud,
M. Fodor, and C. Viollet.
1994.
The neurobiology of somatostatin.
Crit. Rev. Neurobiol.
8:25-44[Medline].
|
| 6.
|
Fan, C. M., and T. Maniatis.
1990.
A DNA-binding protein containing two widely separated zinc finger motifs that recognize the same DNA sequence.
Genes Dev.
4:29-42[Abstract/Free Full Text].
|
| 7.
|
Fodor, M.,
A. Slama,
V. Guillaume,
C. Videau,
Z. Csaba,
C. Oliver, and J. Epelbaum.
1997.
Distribution and pharmacological characterization of somatostatin receptor binding sites in the sheep brain.
J. Chem. Neuroanat.
12:175-182[Medline].
|
| 8.
|
Gorman, C. M.,
L. F. Moffat, and B. H. Howard.
1982.
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Mol. Cell. Biol.
2:1044-1051[Abstract/Free Full Text].
|
| 9.
|
Katz, D. M.,
H. He, and M. White.
1992.
Transient expression of somatostatin peptide is a widespread feature of developing sensory and sympathetic neurons in the embryonic rat.
J. Neurobiol.
23:855-870[Medline].
|
| 10.
|
Kong, H.,
A. M. DePaoli,
C. D. Breder,
K. Yasuda,
G. I. Bell, and T. Reisin.
1994.
Differential expression of messenger RNAs for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brain: analysis by RNA blotting and in situ hybridization histochemistry.
Neuroscience
59:175-184[Medline].
|
| 11.
|
Makino, R.,
K. Akiyama,
J. Yasuda,
S. Mashiyama,
S. Honda,
T. Sekiya, and K. Hayashi.
1994.
Cloning and characterization of a c-myc intron binding protein (MIBP1).
Nucleic Acids Res.
22:5679-5685[Abstract/Free Full Text].
|
| 12.
|
Maubert, E.,
A. Slama,
P. Ciofi,
C. Viollet,
G. Tramu,
J. P. Dupouy, and J. Epelbaum.
1994.
Developmental patterns of somatostatin-receptors and somatostatin-immunoreactivity during early neurogenesis in the rat.
Neuroscience
62:317-325[Medline].
|
| 13.
|
Meyerhof, W.,
I. Wulfsen,
C. Schönrock,
S. Fehr, and D. Richter.
1992.
Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain.
Proc. Natl. Acad. Sci. USA
89:10267-10271[Abstract/Free Full Text].
|
| 14.
|
Mitchelmore, C.,
C. Traboni, and R. Cortese.
1991.
Isolation of two cDNAs encoding zinc finger proteins which bind to the alpha 1-antitrypsin promoter and to the major histocompatibility complex class I enhancer.
Nucleic Acids Res.
19:141-147[Abstract/Free Full Text].
|
| 15.
|
Moser, M.,
A. Imhof,
A. Pscherer,
R. Bauer,
W. Amselgruber,
F. Sinowatz,
F. Hofstadter,
R. Schule, and R. Buettner.
1995.
Cloning and characterization of a second AP-2 transcription factor: AP-2 beta.
Development
121:2779-2788[Abstract].
|
| 16.
|
Moser, M.,
A. Pscherer,
C. Roth,
J. Becker,
G. Mucher,
K. Zerres,
C. Dixkens,
J. Weis,
L. Guay-Woodford,
R. Buettner, and R. Fassler.
1997.
Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta.
Genes Dev.
11:1938-1948[Abstract/Free Full Text].
|
| 17.
|
Nomura, N.,
M. J. Zhao,
T. Nagase,
T. Maekawa,
R. Ishizaki,
S. Tabata, and S. Ishii.
1991.
HIV-EP2, a new member of the gene family encoding the human immunodeficiency virus type 1 enhancer-binding protein. Comparison with HIV-EP1/PRDII-BF1/MBP-1.
J. Biol. Chem.
266:8590-8594[Abstract/Free Full Text].
|
| 18.
|
O'Carroll, A. M.,
S. J. Lolait,
M. König, and L. C. Mahan.
1992.
Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28.
Mol. Pharmacol.
42:939-946[Abstract].
|
| 19.
|
Patel, Y. C.,
M. T. Greenwood,
R. Panetta,
L. Demchyshyn,
H. Niznik, and C. B. Srikant.
1995.
The somatostatin receptor family.
Life Sci.
57:1249-1265[Medline].
|
| 20.
|
Pscherer, A.,
U. Dörflinger,
J. Kirfel,
K. Gawlas,
J. Ruschoff,
R. Buettner, and R. Schüle.
1996.
The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene.
EMBO J.
15:6680-6690[Medline].
|
| 21.
|
Rohrer, L.,
F. Raulf,
C. Bruns,
R. Buettner,
F. Hofstaedter, and R. Schuele.
1993.
Cloning and characterization of a fourth human somatostatin receptor.
Proc. Natl. Acad. Sci. USA
90:4196-4200[Abstract/Free Full Text].
|
| 22.
|
Ron, D.,
A. R. Brasier, and J. F. Habener.
1991.
Angiotensinogen gene-inducible enhancer-binding protein 1, a member of a new family of large nuclear proteins that recognize nuclear factor B-binding sites through a zinc finger motif.
Mol. Cell. Biol.
11:2887-2895[Abstract/Free Full Text].
|
| 23.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 24.
|
Schindler, M.,
K. A. Harrington,
P. P. Humphrey, and P. C. Emson.
1995.
Cellular localisation and co-expression of somatostatin receptor messenger RNAs in the human brain.
Brain Res. Mol. Brain Res.
34:321-326[Medline].
|
| 25.
|
Schindler, M.,
S. Holloway,
P. P. Humphrey,
H. Waldvogel,
R. L. Faull,
W. Berger, and P. C. Emson.
1998.
Localization of the somatostatin sst2(a) receptor in human cerebral cortex, hippocampus and cerebellum.
Neuroreport
9:521-525[Medline].
|
| 26.
|
Seeler, J. S.,
C. Muchardt,
A. Suessle, and R. B. Gaynor.
1994.
Transcription factor PRDII-BF1 activates human immunodeficiency virus type 1 gene expression.
J. Virol.
68:1002-1009[Abstract/Free Full Text].
|
| 27.
|
Soosaar, A.,
A. Chiaramello,
M. X. Zuber, and T. Neuman.
1994.
Expression of basic-helix-loop-helix transcription factor ME2 during brain development and in the regions of neuronal plasticity in the adult brain.
Brain Res. Mol. Brain Res.
25:176-180[Medline].
|
| 28.
|
Tannenbaum, G. S.,
W. H. Zhang,
M. Lapointe,
P. Zeitler, and A. Beaudet.
1998.
Growth hormone-releasing hormone neurons in the arcuate nucleus express both Sst1 and Sst2 somatostatin receptor genes.
Endocrinology
139:1450-1453[Abstract/Free Full Text].
|
| 28a.
|
Thoss, V. S.,
J. Perez,
D. Duc, and D. Hoyer.
1995.
Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain.
Neuropharmacology
34:1673-1688[Medline].
|
| 28b.
|
Thoss, V. S.,
D. Duc, and D. Hoyer.
1996.
Somatostatin receptors in the developing rat brain.
Eur. J. Pharmacol.
297:145-155[Medline].
|
| 29.
|
Umesono, K.,
K. K. Murakami,
C. C. Thompson, and R. M. Evans.
1991.
Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors.
Cell
65:1255-1266[Medline].
|
| 30.
|
Vallarino, M.,
M. Mathieu,
B. D'Aniello, and R. K. Rastogi.
1998.
Distribution of somatostatin-like immunoreactivity in the brain of the frog, Rana esculenta, during development.
Brain Res. Dev. Brain Res.
106:13-23[Medline].
|
| 31.
|
van't-Veer, L. J.,
P. M. Lutz,
K. J. Isselbacher, and R. Bernards.
1992.
Structure and expression of major histocompatibility complex-binding protein 2, a 275-kDa zinc finger protein that binds to an enhancer of major histocompatibility complex class I genes.
Proc. Natl. Acad. Sci. USA
89:8971-8975[Abstract/Free Full Text].
|
| 32.
|
Yamada, Y.,
S. R. Post,
K. Wang,
H. Tager,
G. Bell, and S. Seino.
1992.
Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.
Proc. Natl. Acad. Sci. USA
89:251-255[Abstract/Free Full Text].
|
| 33.
|
Yasuda, K.,
S. Rens-Domiano,
C. D. Breder,
S. F. Law,
C. B. Saper,
T. Reisine, and G. I. Bell.
1992.
Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylclase.
J. Biol. Chem.
267:20422-20428[Abstract/Free Full Text].
|
Molecular and Cellular Biology, May 1999, p. 3736-3747, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.